| Abstract | We developed a bioartificial liver (BAL) containing human hepatoblastoma cell line, HepG2, with the addition of ammonia removal activity by transfecting a glutamine synthetase (GS) gene and estimated the efficacy using pigs with ischemic liver failure. GS-HepG2 cells showed 15% ammonia removal activity of porcine hepatocytes, while unmodified HepG2 had no such activity. The established GS-HepG2 cells were grown in a circulatory flow bioreactor to 3.5-4.1 x 10(9) cells. Survival time of the animals treated with GS-HepG2 BAL was significantly prolonged compared to the cell-free control (14.52 +/- 5.24 h vs. 8.53 +/- 2.52 h) and the group treated with the BAL consisting of unmodified wild-type HepG2 (9.58 +/- 4.52 h). Comparison showed the cell-containing BAL groups to have significantly fewer incidences of increased brain pressure. Thus, the GS-HepG2 BAL treatment resulted in a significant improvement of survival time and pathological parameters in pigs with ischemic liver failure. |
| Authors | Shin Enosawa, Tomoyuki Miyashita, Tomohiro Saito, Takeshi Omasa, Toshiharu Matsumura
(Affiliation: Department of Innovative Surgery, National Research Institute for Child Health and Development, Tokyo, Japan. senosawa at nch.go.jp)
|
| Journal | Cell transplantation
(Cell Transplant)
Vol. 15
Issue 10
Pg. 873-80
( 2006)
ISSN: 0963-6897 United States |
| PMID | 17299991
(Publication Type: Journal Article)
|
| Chemical References |
|
| Topics |
- Animals
- Bioreactors
- Cell Culture Techniques
- Cell Line, Tumor
- Cell Transplantation
- Cricetinae
- Disease Models, Animal
- Female
- Glutamate-Ammonia Ligase
(genetics, metabolism)
- Humans
- Liver Failure
(metabolism, mortality, therapy)
- Liver, Artificial
- Male
- Models, Biological
- Survival Rate
- Swine
- Transfection
|
